KDR and neoplasm: However, single treatment of sunitinib only partially inhibited bone destruction and partially decreased the number of osteoclasts (Figs 3 and 4C), suggesting that only inhibition of FMS, or dual inhibition of VEGFRs/FMS, is not sufficient for the suppression of tumor-induced osteoclast formation and it is possible that MET signaling might complement FMS and/or VEGFR signaling in osteoclasts.